# Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)

> **NCT01890421** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 426 (actual)

## Conditions studied

- Coronary Artery Disease

## Interventions

- **DRUG:** Gadobutrol (Gadovist, Gadavist, BAY86-4875)

## Key facts

- **NCT ID:** NCT01890421
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07-19
- **Primary completion:** 2015-04-10
- **Final completion:** 2017-08-31
- **Target enrollment:** 426 (ACTUAL)
- **Last updated:** 2018-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01890421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01890421, "Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01890421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*